2017至2019年丹麦东部动脉瘤性蛛网膜下腔出血治疗患者的死亡率
该回顾性队列纳入2017年1月1日至2019年12月31日在哥本哈根大学医院接受动脉瘤夹闭或血管内治疗的317例破裂动脉瘤患者,随访12个月。30天、3个月和12个月累积死亡率分别为10.7%、12.9%和16.1%,最常见死因为严重原发性出血(52.9%),可预防原因约占22%。
要点
- 30天、3个月、12个月累积死亡率分别为10.7%、12.9%、16.1%。
- 最常见死因为严重原发性出血(52.9%),其次为感染(15.7%)和再出血(11.8%)。
- 入院WFNS评分>3、Fisher评分>3、术前脑积水和术前再出血与死亡风险升高显著相关。
核心结论
- 接受动脉瘤闭塞治疗的aSAH患者死亡率可观,可预防原因约占死亡的22%;术前和术后再出血的发生提示可通过缩短aSAH至动脉瘤闭塞时间和持续改进动脉瘤闭塞方法来进一步降低死亡率。
研究设计与样本
- 回顾性队列研究,纳入2017年1月1日至2019年12月31日在哥本哈根大学医院接受手术夹闭或血管内治疗破裂动脉瘤的所有患者,共317例,随访12个月。
- 收集生命状态、死因、合并症、治疗及入院时临床表现数据;以95%置信区间估计绝对死亡风险随时间的变化;使用logistic回归模型以比值比(OR)及95%置信区间估计潜在危险因素与死亡的关联。
主要发现
- 30天、3个月和12个月总体累积死亡率分别为10.7%、12.9%和16.1%。
- 最常见死因为严重原发性出血(52.9%),其次为感染(15.7%)和再出血(11.8%)。
- 入院WFNS评分>3、Fisher评分>3、术前脑积水和术前再出血与死亡风险升高显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to investigate (1) the 30-day, 3-month, and 12-month cumulative mortalities for patients who underwent aneurysm occlusion, and (2) the causes of death, and (3) the potential risk factors for death. METHODS: All patients who underwent surgical clipping or endovascular treatment of a ruptured aneurysm at Copenhagen University Hospital, during the period of January 1, 2017-December 31, 2019, were included and followed up for 12 months. Data regarding vital status, causes of death, comorbidities, treatment, and clinical presentations on admission was collected. The absolute mortality risk was estimated as a function of time with a 95% confidence interval. The associations between potential risk factors and death were estimated as odds ratios with 95% confidence intervals using logistic regression models. RESULTS: A total of 317 patients were included. The overall cumulative mortalities after 30 days, 3 months, and 12 months were 10.7%, 12.9%, and 16.1%, respectively. The most common cause of death was severe primary hemorrhage (52.9%), followed by infections (15.7%) and rebleeding (11.8%). WFNS score > 3 and Fisher score > 3 on admission, preprocedural hydrocephalus, and preprocedural rebleeding were found significantly associated with higher risk of death. CONCLUSIONS: Considerable mortality was seen. Possible preventable causes accounted for approximately 22% of the deaths. The occurrence of both pre- and postprocedural rebleeding's indicates an opportunity of further improvement of the mortality by (1) further reduction of time from aSAH to aneurysm occlusion and (2) continuous efforts in improving methods of aneurysm occlusion.
引用
- Stauning AT, Eriksson F, Benndorf G, et al. Mortality among patients treated for aneurysmal subarachnoid hemorrhage in Eastern Denmark 2017-2019. Acta Neurochir (Wien). 2022. PMID: 35864221. doi:10.1007/s00701-022-05303-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。